Identification and characterization by 16S rDNA analysis of viable bacterial colonies isolated from oral medicines based on inactivated or lysed pathogenic bacteria

Biologicals

Volumn 31, Issue 1, 2003, Pages 39-43

  Studer, Edgar ^a   Candrian, Urs ^a,b  

^a FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^b Swissmedic   (Switzerland)

Author keywords

Bacterial colonies; Oral medicines; Pathogenic bacteria

Indexed keywords

AGAR; CENTRAL STIMULANT AGENT; DNA 16S; IMMUNOMODULATING AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; CACAO; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA DETERMINATION; DNA SEQUENCE; ESCHERICHIA COLI; GENE IDENTIFICATION; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA OZEANAE; KLEBSIELLA PNEUMONIAE; MORAXELLA CATARRHALIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; SWITZERLAND;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE;

EID: 0037336664     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1056(02)00091-X     Document Type: Article

References (16)

1. Eggenberger K. Les infections de voies respiratoires les plus fréquentes chez l'enfant dans la pratique ambulatoire. Ars Med. 83:(Suppl):1993;24-30.
2. Houston M.S., Silverstein M.D., Suman V.J. Community-acquired lower respiratory tract infection in the elderly: a community-based study of incidence and outcome. J Am Board Fam Pract. 8:1995;347-356.
3. Macfarlane J.T., Colville A., Guion A., Macfarlane R.M., Rose D.H. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 341:1993;511-514.
4. Speich R. Akute und chronische bronchitis. Ther Umsch. 4:1992;227-233.
5. Jacobs M.R. Respiratory tract infection: epidemiology and surveillance. J Chemother. 9:(Suppl 3):1997;10-17.
6. Jones R.N. The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm. 56:(Suppl 3):1999;S4-S11.
7. Puigdollers J.M., Serna G.R., Hernandez del Rey I., Barruffet M.T., Torroella J.J. Immunoglobulin production in man stimulated by an orally administered bacterial lysate. Respiration. 40:1980;142-149.
8. Neutra M.R., Kraehenbuhl J.-P. Antigen uptake by M cells for effective mucosal vaccines. Kiyono H., Ogra P.L., McGhee J.R. Mucosal vaccines. 1996;41-55 Academic Press, San Diego, CA.
9. Staats H.F., McGhee J.R. Application of basic principles of mucosal immunity to vaccine development. Kiyono H., Ogra P.L., McGhee J.R. Mucosal vaccines. 1996;17-39 Academic Press, San Diego, CA.
10. Cvoriscec B., Ustar M., Pardon R., Palecek I., Stipic-Markovic A., Zimic B. Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration. 55:1989;129-135.
11. Derenne J.P., Delclaux B. Clinical experience with OM-85 BV in upper and lower respiratory tract infections. Respiration. 59:1992;28-31.
12. Grevers G., Palacios O.A., Rodriguez B., Abel S., van Aubel A. Treatment of recurrent respiratory tract infections with a polyvalent bacterial lysate: results of an open, prospective, multinational study. Adv Ther. 17:2000;103-116.
13. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration. 58:1991;150-154.
14. Rutishauser M., Pitzke P., Grevers G., van Aubel A., Elsasser U., Kammereit A. Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. Adv Ther. 15:1998;330-341.
15. General texts. European pharmacopeia supplement 2001. Strasbourg, Council of Europe, 2000. 294pp.
16. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of clinical microbiology. 1995;ASM Press, Washington, DC.